Drug Profile
Research programme: targeted cancer therapeutics - Avidity Biosciences
Alternative Names: Antibody-siRNA complexes; Antibody-siRNA conjugates; ASC™Latest Information Update: 17 Nov 2021
Price :
$50
*
At a glance
- Originator Avidity NanoMedicines
- Developer Avidity Biosciences
- Class Recombinant fusion proteins
- Mechanism of Action Cell modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for research development in Cancer in USA
- 17 Jun 2014 Early research in Cancer in USA (unspecified route)